Canagliflozin
An SGLT2 inhibitor that lowers blood sugar in type 2 diabetes by preventing the kidneys from reabsorbing glucose, causing it to be excreted in the urine. Beyond glucose control, it reduces the risk of cardiovascular events and slows progression of diabetic kidney disease. Side effects include urinary and genital infections and a rare risk of lower limb amputation.
Moleküler Ağırlık
444,5170 g/mol
LogP
3,20
TPSA
118,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
İlaç Sınıfları
Etki Mekanizması
Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.
2D Yapı
Cite this structure
Embed this structure
SMILES
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O
InChI
InChI=1S/C24H25FO5S.H2O/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14;/h2-10,19,21-24,26-29H,11-12H2,1H3;1H2/t19-,21-,22+,23-,24+;/m1./s1
Molecular Formula
C24H25FO5S
HBD / HBA
4 / 7
Döndürülebilir Bağlar
5
Ağır Atomlar
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
An SGLT2 inhibitor that lowers blood sugar in type 2 diabetes by preventing the kidneys from reabsorbing glucose, causing it to be excreted in the urine. Beyond glucose control, it reduces the risk of cardiovascular events and slows progression of diabetic kidney disease. Side effects include urinary and genital infections and a rare risk of lower limb amputation.
Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.
Key pharmacokinetic parameters for Canagliflozin: Half-life: 10.6 hours.
Yes, Canagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594217. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 24812758. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="canagliflozin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/canagliflozin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/canagliflozin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/canagliflozin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="canagliflozin"></drugfyi-drug>